Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP14 | P54578 | 11/20 | 1.00 |
| ▸ | USP7 | Q93009 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.97 |
| ▸ | HPGD | P15428 | 3/20 | 0.81 |
| ▸ | RAB9A | P51151 | 4/20 | 0.78 |
| ▸ | NPC1 | O15118 | 3/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.78 |
| ▸ | USP5 | P45974 | 2/20 | 0.78 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17949751 | 1.00 | USP14 (1.00) | USP14USP7SMN1; SMN2HPGDRAB9A | |
| SCHEMBL6921679 | 0.99 | SMN1; SMN2 (1.00) | USP14USP7SMN1; SMN2HPGDRAB9A | |
| SCHEMBL23524546 | 0.90 | USP14 (0.81) | USP14USP7SMN1; SMN2HPGDRAB9A | |
| SCHEMBL16079020 | 0.90 | SMN1; SMN2 (1.00) | USP14USP7SMN1; SMN2HPGDRAB9A | |
| SCHEMBL17949834 | 0.89 | SMN1; SMN2 (0.82) | USP14USP7SMN1; SMN2HPGDRAB9A | |
| SCHEMBL23524510 | 0.89 | SMN1; SMN2 (0.83) | USP14USP7SMN1; SMN2HPGDRAB9A | |
| SCHEMBL23524519 | 0.88 | SMN1; SMN2 (0.81) | USP14USP7SMN1; SMN2HPGDRAB9A | |
| SCHEMBL6922583 | 0.88 | SMN1; SMN2 (0.97) | USP14USP7SMN1; SMN2HPGDRAB9A | |
| SCHEMBL23524504 | 0.88 | USP14 (0.78) | USP14USP7SMN1; SMN2HPGDRAB9A | |
| SCHEMBL17949721 | 0.88 | USP14 (0.78) | USP14USP7SMN1; SMN2HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240108612-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF PROTAC, INCLUDING IU1-SERIES UBIQUITIN-SPECIFIC PROTEASE 14 INHIBITOR AS ACTIVE INGREDIENT | DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2024-04-04 | — | — | US | claimed |
| CN-114699388-B | Bionic nano-drug carrier for targeted treatment of deep tumors and preparation method thereof | 成都医学院 | 2023-05-30 | — | — | CN | claimed |
| WO-2022250363-A1 | PHARMACEUTICAL COMPOSITION COMPRISING IU1-LINEAGE UBIQUITIN-SPECIFIC PROTEASE 14 INHIBITOR AS ACTIVE INGREDIENT FOR ENHANCING ANTICANCER EFFECT OF PROTAC | 재단법인대구경북과학기술원 | 2022-12-01 | — | — | WO | claimed |
| CN-114699388-A | Bionic nano-drug carrier for targeted therapy of deep tumor and preparation method thereof | 成都医学院 | 2022-07-05 | — | — | CN | claimed |
| US-20250090504-A1 | SMALL MOLECULE PEPTIDOMIMETIC FOR THE TREATMENT OF TAUOPATHIES | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-03-20 | — | — | US | disclosed |
| EP-4463175-A1 | SMALL MOLECULE PEPTIDOMIMETIC FOR THE TREATMENT OF TAUOPATHIES | Stealth BioTherapeutics Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-118829440-A | Small molecule peptide mimetics for the treatment of tauopathies | 康德生物医疗有限公司 | 2024-10-22 | — | — | CN | disclosed |
| US-20240108612-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF PROTAC, INCLUDING IU1-SERIES UBIQUITIN-SPECIFIC PROTEASE 14 INHIBITOR AS ACTIVE INGREDIENT | DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2024-04-04 | — | — | US | disclosed |
| WO-2023133321-A1 | SMALL MOLECULE PEPTIDOMIMETIC FOR THE TREATMENT OF TAUOPATHIES | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| CN-114699388-B | Bionic nano-drug carrier for targeted treatment of deep tumors and preparation method thereof | 成都医学院 | 2023-05-30 | — | — | CN | disclosed |
| CN-114699388-B | Bionic nano-drug carrier for targeted treatment of deep tumors and preparation method thereof | 成都医学院 | 2023-05-30 | — | — | CN | disclosed |
| WO-2022250363-A1 | PHARMACEUTICAL COMPOSITION COMPRISING IU1-LINEAGE UBIQUITIN-SPECIFIC PROTEASE 14 INHIBITOR AS ACTIVE INGREDIENT FOR ENHANCING ANTICANCER EFFECT OF PROTAC | 재단법인대구경북과학기술원 | 2022-12-01 | — | — | WO | disclosed |
| US-20150335652-A1 | USP14 Inhibitors for Treating or Preventing Viral Infections | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2015-11-26 | — | — | US | disclosed |
| US-20140275169-A1 | Combination Therapies for Enhancing Protein Degradation | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275169-A1 | Combination Therapies for Enhancing Protein Degradation | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014116228-A1 | USP14 INHIBITORS FOR TREATING OR PREVENTING VIRAL INFECTIONS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-07-31 | — | — | WO | disclosed |
| US-20130045992-A1 | Compositions and Methods for Enhancing Proteasome Activity | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130045992-A1 | Compositions and Methods for Enhancing Proteasome Activity | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130045992-A1 | Compositions and Methods for Enhancing Proteasome Activity | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-02-21 | — | — | US | disclosed |
| WO-2011094545-A2 | COMPOSITIONS AND METHODS FOR ENHANCING PROTEASOME ACTIVITY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150335652-A1 | USP14 Inhibitors for Treating or Preventing Viral Infections | USP14, USP1, USP13 | USP14 1/4885USP7 7/4885SMN1; SMN2 1593/4885 |
| US-20250090504-A1 | SMALL MOLECULE PEPTIDOMIMETIC FOR THE TREATMENT OF TAUOPATHIES | MAPT, PSEN1, PSEN2 | USP14 2394/4885USP7 2880/4885SMN1; SMN2 7/4885 |
| US-20240108612-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF PROTAC, INCLUDING IU1-SERIES UBIQUITIN-SPECIFIC PROTEASE 14 INHIBITOR AS ACTIVE INGREDIENT | USP14, UBA1, USP1 | USP14 1/4885USP7 18/4885SMN1; SMN2 2748/4885 |
| US-20130045992-A1 | Compositions and Methods for Enhancing Proteasome Activity | PSMG3, PSMB11, PSME3 | USP14 6/4885USP7 43/4885SMN1; SMN2 307/4885 |
| US-20140275169-A1 | Combination Therapies for Enhancing Protein Degradation | HSPA2, HSPBP1, HSPH1 | USP14 10/4885USP7 72/4885SMN1; SMN2 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.